Kairos Pharma income statement data for the quarter ended Dec 2025. This income statement covers 9 quarters of results from Sep 2023 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||
| Revenue | 100.00M | ||||||||
| Operating items | |||||||||
| Research & DevelopmentR&D | 0.03M | 0.01M | 0.17M | 0.06M | 0.01M | 0.17M | 0.49M | 0.50M | |
| Selling, General & AdministrativeSG&A | 0.25M | 1.08M | 0.12M | 0.16M | 0.37M | 1.27M | 0.77M | 0.96M | |
| Operating ExpensesOpex | 0.29M | 1.09M | 0.29M | 0.22M | 0.38M | 1.45M | 1.27M | 1.46M | |
| Operating IncomeOp. Inc | -0.29M | -1.09M | -0.29M | -0.22M | -0.38M | -1.45M | -1.27M | -1.46M | |
| EBIT | -0.29M | -1.09M | -0.29M | -0.22M | -0.38M | -1.45M | -1.27M | -1.46M | |
| Non-operating items | |||||||||
| Non Operating Interest Expenses | 0.01M | 0.00M | 0.02M | 0.01M | 0.54M | 0.13M | |||
| Interest & Investment IncomeInt & Inv Inc | 0.00M | 0.03M | |||||||
| Non Operating IncomeNon Op. Inc. | -0.03M | -0.03M | -0.04M | -0.03M | -0.66M | 0.47M | 0.00M | 0.03M | |
| Net income details | |||||||||
| EBT | -0.30M | -1.09M | -0.30M | -0.23M | -0.92M | -1.58M | -1.26M | -1.42M | |
| Profit After TaxPAT | -0.31M | -1.12M | -0.32M | -0.25M | -1.05M | -0.98M | -1.26M | -1.42M | |
| Income from Continuing OperationsIncome (Continuing) | -0.30M | -1.09M | -0.30M | -0.23M | -0.92M | -1.58M | -1.26M | -1.42M | |
| Consolidated Net IncomeConsol Net Inc. | -0.30M | -1.09M | -0.30M | -0.23M | -0.92M | -1.58M | -1.26M | -1.42M | |
| Income towards Parent CompanyParent Net Inc | -0.30M | -1.09M | -0.30M | -0.23M | -0.92M | -1.58M | -1.26M | -1.42M | |
| Net Income towards Common StockholdersNet Income | -0.30M | -1.09M | -0.30M | -0.23M | -0.92M | -1.58M | -1.26M | -1.42M | |
| Additional items | |||||||||
| EPS (Basic) | -0.03 | -0.11 | -0.03 | -0.02 | -0.08 | -0.14 | -0.08 | -0.08 | |
| EPS (Diluted) | -0.03 | -0.11 | -0.03 | -0.02 | -0.08 | -0.14 | -0.08 | -0.08 | |
| Shares Outstanding | 10.33M | 10.38M | 10.56M | 10.56M | 10.91M | 11.36M | 15.88M | 17.21M | 18.43M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 10.33M | 10.38M | 10.56M | 10.56M | 10.91M | 11.36M | 15.88M | 17.21M | 18.43M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 10.33M | 10.56M | 10.56M | 10.56M | 12.85M | 11.36M | 15.83M | 17.74M | 20.82M |
| EBITDA | -0.29M | -1.09M | -0.29M | -0.22M | -0.38M | -1.45M | -1.27M | -1.46M | |
| Interest ExpensesInt Expense | 0.01M | 0.00M | 0.02M | 0.01M | 0.54M | 0.13M |